Ongoing Study of Adjuvant Elacestrant: Phase 3 ELEGANT | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Ongoing Study of Adjuvant Elacestrant: Phase 3 ELEGANT | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
10 months ago
targetedonc.com
Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer | OncLive
Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer | OncLive
Jun 14, 2022
onclive.com
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
2:35
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
354 viewsDec 13, 2024
YouTubeOncLive
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer
0:57
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer
111 viewsDec 11, 2024
YouTubeOncLive
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2:01
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Apr 9, 2025
targetedonc.com
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Nov 9, 2022
targetedonc.com
New Frontiers in Adjuvant Care: Evaluating Elacestrant in the ELEGANT Trial | CancerNetwork
New Frontiers in Adjuvant Care: Evaluating Elacestrant in the ELEGANT Trial | CancerNetwork
1 month ago
cancernetwork.com
Elacestrant Targeted Therapy for ER /HER2– Metastatic Breast Cancer: Early Phase Trial Findings | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Jul 3, 2024
targetedonc.com
1:07
Tumori: oncologa Del Mastro, 'elacestrant passo avanti in cura cancro seno metastatico'
10 months ago
MSNAdnkronos
Oral SERDs in HR Positive Breast Cancer: Current Role and Patient Selection for Elacestrant | OncLive
4 months ago
onclive.com
EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER /HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting | OncLive
Dec 22, 2022
onclive.com
8:53
Elacestrant in ER+/HER2- mBC with ESR1-mut tumors: Overview of the EMERALD subgroup analyses
3K viewsApr 22, 2025
YouTubeCOR2ED The Heart of Medical Education
0:50
FDA approves Elacestrant (Orserdu) for ER-positive, HER2-negative, ESR1-mutated breast cancer
1.4K viewsJan 29, 2023
YouTubemedXclusive Learning
0:58
🧬 C’è un nuovo farmaco per il tumore al seno 💊 Si chiama Elacestrant 👉 È il primo SERD orale: un farmaco che blocca e degrada il recettore degli estrogeni, interrompendo il “segnale” che fa crescere il tumore. 👩‍⚕️ È indicato per: Donne in post-menopausa e uomini con tumore al seno HR e HER2-, in fase avanzata o metastatica (dopo il fallimento di una terapia endocrina). 🧬 La vera novità? ✅ Funziona anche in presenza della mutazione ESR1, che rende inefficaci molte altre terapie ✅ Si assume
2.7K views11 months ago
FacebookDott. Jonathan Granatieri - Farmacista
3:07
The EMERALD Trial: Elacestrant in Patients with HR , HER2- Advanced Breast Cancer | OncLive
Feb 9, 2024
onclive.com
Tumore: elacestrant nuova terapia in aiuto a pazienti con carcinoma mammario
Jun 20, 2024
Il Sole 24 ORE
1:44
Dr Rugo on Elacestrant-Based Combinations in ER /HER2– Metastatic Breast Cancer | OncLive
Dec 11, 2024
onclive.com
11:25
EMERALD Study Design and Results for Elacestrant  | OncLive
Jul 8, 2024
onclive.com
Imlunestrant vs Elacestrant: MOA and Clinical Trial Differences | Oncology Nursing News
7 months ago
oncnursingnews.com
Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER Breast Cancer Treatment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Dec 12, 2024
targetedonc.com
6:07
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER /HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States | OncLive
Dec 18, 2024
onclive.com
9:11
Perspectives on a Patient with ESR1m and PIK3CA Mutations
63 views3 months ago
YouTubeORSERDU® (elacestrant) HCP
EMERALD: Elacestrant in ER /HER2- Advanced Breast Cancer | OncLive
Jan 23, 2024
onclive.com
Dr O’Shaughnessy on the Impetus for the ELEGANT Study in High-Risk Breast Cancer | OncLive
3 months ago
onclive.com
EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Nov 25, 2024
targetedonc.com
1:16
New Oral SERD Elacestrant Shows Promise in ER+ Breast Cancer
78 views3 weeks ago
YouTubeThe Oncology Brief
ESR1 Mutations in Focus: Are PROTACs the Next Breakthrough? | Francisco J. Esteva, MD, PhD
5.5K views3 weeks ago
linkedin.com
6:50
Sherri’s ORSERDU (elacestrant) Story | ESR1 Testing and Disease Progression
95 views7 months ago
YouTubeORSERDU® (elacestrant)
5:30
ER+ metastatic breast cancer: Elacestrant and beyond
271 viewsApr 2, 2024
YouTubeCOR2ED The Heart of Medical Education
2:37
Elacestrant: A New Weapon Against Advanced Estrogen Receptor-Positive Breast Cancer
1.1K viewsApr 17, 2024
YouTubePharmacology Insights
See more
Static thumbnail place holder